Strs Ohio Has $313,000 Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Strs Ohio increased its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) by 11.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 19,900 shares of the biotechnology company’s stock after buying an additional 2,000 shares during the period. Strs Ohio’s holdings in Aclaris Therapeutics were worth $313,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ACRS. JPMorgan Chase & Co. lifted its position in Aclaris Therapeutics by 20.0% during the 1st quarter. JPMorgan Chase & Co. now owns 44,650 shares of the biotechnology company’s stock worth $770,000 after buying an additional 7,448 shares in the last quarter. MetLife Investment Management LLC lifted its position in Aclaris Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 26,282 shares of the biotechnology company’s stock worth $453,000 after buying an additional 9,700 shares in the last quarter. Rhumbline Advisers lifted its position in Aclaris Therapeutics by 18.1% during the 1st quarter. Rhumbline Advisers now owns 55,194 shares of the biotechnology company’s stock worth $952,000 after buying an additional 8,469 shares in the last quarter. Allianz Asset Management GmbH lifted its position in Aclaris Therapeutics by 44.2% during the 1st quarter. Allianz Asset Management GmbH now owns 81,965 shares of the biotechnology company’s stock worth $1,413,000 after buying an additional 25,125 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Aclaris Therapeutics by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 2,728,820 shares of the biotechnology company’s stock valued at $47,045,000 after purchasing an additional 10,713 shares during the period. Institutional investors and hedge funds own 95.33% of the company’s stock.

Insider Buying and Selling

In related news, Director Neal Walker sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total transaction of $381,250.00. Following the completion of the sale, the director now directly owns 1,220,763 shares of the company’s stock, valued at approximately $18,616,635.75. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Joseph Monahan sold 5,000 shares of the stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the completion of the sale, the insider now directly owns 96,386 shares of the company’s stock, valued at approximately $1,530,609.68. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Neal Walker sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total value of $381,250.00. Following the sale, the director now directly owns 1,220,763 shares of the company’s stock, valued at $18,616,635.75. The disclosure for this sale can be found here. In the last three months, insiders sold 59,156 shares of company stock valued at $956,448. 6.70% of the stock is owned by corporate insiders.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS opened at $16.68 on Friday. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -12.93 and a beta of 0.52. The firm’s 50 day simple moving average is $16.36 and its 200 day simple moving average is $16.00. Aclaris Therapeutics, Inc. has a fifty-two week low of $9.26 and a fifty-two week high of $18.96.

Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.09. The business had revenue of $19.02 million for the quarter, compared to the consensus estimate of $1.61 million. Aclaris Therapeutics had a negative net margin of 349.26% and a negative return on equity of 39.41%. Equities research analysts expect that Aclaris Therapeutics, Inc. will post -1.39 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ACRS shares. The Goldman Sachs Group started coverage on shares of Aclaris Therapeutics in a research report on Thursday, December 1st. They set a “buy” rating and a $25.00 target price on the stock. SVB Leerink restated an “outperform” rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. StockNews.com started coverage on shares of Aclaris Therapeutics in a research report on Wednesday, October 12th. They set a “sell” rating on the stock. Stifel Nicolaus started coverage on shares of Aclaris Therapeutics in a research report on Tuesday, December 13th. They set a “buy” rating and a $29.00 target price on the stock. Finally, BTIG Research started coverage on shares of Aclaris Therapeutics in a research report on Thursday, October 6th. They set a “buy” rating and a $32.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, Aclaris Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Aclaris Therapeutics Profile

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.